Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Published . Updated .
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
Directly affected
- LLY Eli Lilly
Named in this report.
Indirectly affected
- ACHC ACADIA HEALTHCARE COMPANY INC
GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare, acadia. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ASND ASCENDIS PHARMA A/S
GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- ATYR ATYR PHARMA INC COM NEW
GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- BBIO BRIDGEBIO PHARMA INC
GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- DVA DaVita HealthCare Partners, Inc.
GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
- GEHC GE HEALTHCARE TECHNOLOGIES I
GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article.
Price reaction, T-5 to T+3
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
Source: BioPharma Dive
How far Eli Lilly (LLY) has moved since 25 Sep 2026
Since the first closing price after “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” Eli Lilly (LLY) is +4.64%. The S&P 500 fund (SPY) is +0.15% over the same days, a +4.49% difference versus the market.
Filings that name Eli Lilly (LLY) around 25 Sep 2026
- Gilbert Cisneros sell BridgeBio Pharma (BBIO) ($1,001 - $15,000). That is 4 days after publication, inside 30 days. The filing is listed beside the story “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 14 days before publication, inside 30 days. The filing is listed beside the story “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data.”
- Rohit Khanna buy Eli Lilly (LLY) ($1,001 - $15,000). That is 21 days before publication, inside 30 days. The filing is listed beside the story “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 53 days before publication, inside 60 days. The filing is listed beside the story “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 57 days before publication, inside 60 days. The filing is listed beside the story “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data.”
- Rohit Khanna buy GE HealthCare Technologies (GEHC) ($1,001 - $15,000). That is 57 days before publication, inside 60 days. The filing is listed beside the story “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data.”
Public disclosure filings, not a recommendation. The filing link is the source document. News use of these reports still sits under 5 U.S.C. § 13107(c).
Who gains and who loses around Eli Lilly (LLY)
Companies mentioned with this story
- LLY Eli Lilly
In “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” Eli Lilly (LLY) is linked, with no stored direction, high confidence. Reason on file: The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY
- ACHC Acadia Healthcare
For “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” Acadia Healthcare (ACHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare, acadia. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ASND Ascendis Pharma A/S
In “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” Ascendis Pharma A/S (ASND) is linked, with no stored direction, medium confidence. Reason on file: GA selected ASND as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- ATYR aTYR PHARMA
For “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” aTYR PHARMA (ATYR) is linked, with no stored direction, medium confidence. Reason on file: GA selected ATYR as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- BBIO BridgeBio Pharma
In “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” BridgeBio Pharma (BBIO) is linked, with no stored direction, medium confidence. Reason on file: GA selected BBIO as a RELATED security because its canonical security name directly matches this event's themes: pharma. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- DVA Davita
For “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” Davita (DVA) is linked, with no stored direction, medium confidence. Reason on file: GA selected DVA as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
- GEHC GE HealthCare Technologies
In “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data,” GE HealthCare Technologies (GEHC) is linked, with no stored direction, medium confidence. Reason on file: GA selected GEHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Eli Lilly (LLY)
The 25 Sep 2026 story “Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data” names Eli Lilly (LLY) because of this story.
Eli Lilly (LLY) is on the page because The reported development directly names ELI LILLY & CO in the summary; GA resolved that company to LLY
Acadia Healthcare (ACHC) is here too. Its reason reads: GA selected ACHC as a RELATED security because its canonical security name directly matches this event's themes: healthcare, acadia. This is an explainable DERIVED market relationship, not a claim that the security was named in the source article
Dates and price levels for Eli Lilly (LLY)
ACHC traded between 26.75 and 32.03 across 20 sessions. The latest close on file is 30.20. ASND traded between 219.69 and 240.84 across 20 sessions. The latest close on file is 229.99. LLY traded between 1131.55 and 1275.56 across 20 sessions. The latest close on file is 1240.65.
A simple score for Eli Lilly (LLY)
46 out of 100
“Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data” scores 46 out of 100. The score uses 1 sources, and 7 linked companies.